Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 35 for “"lamivudine"”.
-
Analysis of Treatment Effect of Lamivudine, Adefovir Add-on Therapy in Patients with Lamivudine Resistant Chronic B-viral Hepatitis
Background: Add on adefovir (ADV) to ongoing lamivudine (LAM) is an established treatment modality for treatment of LAM resistance with chronic hepatitis B. We assessed the long?term efficacy (median follow-up of 20.18 months) of ADV add-on LAM therapy in 89 LAM-resistant patients. Methods: 89 …
-
Analysis of Treatment Effect of Lamivudine plus Adefovir Add-on Therapy in Patients with Lamivudine Resistant Chronic B-viral Hepatitis
목적: 라미부딘은 만성 B형 간염의 1차 치료제로 널리 사용되어 왔으나 내성 발현이 잦은 단점이 있다. 이러한 단점을 극복하기 위해 아데포비어 병합 치료가 사용되고 있으나 한국인을 대상으로 한 연구 결과는 적은 편이다. 저자들은 라미부딘에 내성인 B형 만성 간염 환자를 대상으로 라미부딘과 아데포비어 병합 치료 효과와 바이러스 돌파 현상을 확인하고자 하였다. 방법: 2005년 8월부터 2010년 10월까지 본원에서 라미부딘 투여 중 내성이 발생한 후 아데포비어를 추가？？여 치료한 환자 중 12개월 이상 치료받은 93명을 대상으로 …
-
Multidrug-Resistant Hepatitis B Virus Resulting From Sequential Monotherapy With Lamivudine, Adefovir, and Entecavir: Clonal Evolution During Lamivudine Plus Adefovir Therapy
… developed from sequential monotherapy with lamivudine (LAM), adefovir (ADV), and entecavir (ETV) during LAM plus ADV salvage therapy. METHODS: Sera were obtained from 6 patients who had developed sequential resistance to LAM, ADV, and ETV before and during LAM plus ADV therapy. The HBV …
-
Comparison of Serum HBV DNA Levels between Lamivudine Induced HBeAg Seroconversion and Spontaneous Seroconversion
… is usually lower than the rate in patients with lamivudine induced HBeAg seroconversion in Asians with chronic hepatitis B. The aim of this study was to compare serum HBV DNA levels at the time of HBeAg seroconversion between these two groups. METHODS: We retrospectively analyzed 37 patients with …
-
Emergence of Adefovir-resistant Mutants after Reversion to YMDD Wild-type in Lamivudine-resistant Patients
… rates of cirrhosis and hepatocellular carcinoma. Lamivudine (LAM) is the first nucleoside analogue approved for the treatment of Chronic hepatitis B (CHB) with good potency, safety profile and low cost. However, it frequently results in marked drug resistance, which has been reported to occur up …
-
Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
"본 연구에서는 이전에 라미부딘 및 아데포비어 내성을 보였던 환자를 엔테카비어로 전환하여 치료하여 이후 발생된 바이러스 반응, 엔테카비어 내성 및 라미부딘과 아데포비어 내성변종의 발현을 관찰하였다. 대상 환자는 예전에 라미부딘 내성을 보였던 아데포비어 내성 환자 중에서 6개월 이상 엔테카비어를 복용한 40명의 환자를 대상으로 하였으며 이들 환자에서의 바이러스 반응 및 엔테카비어 내성을 모니터링하였다. 전체 10% 환자에서 24주 동안의 엔테카비어 치료로 HBV DNA가 50 (copies/mL) 이하가 되었으며 40명의 환자 중 …
-
Association of Lamivudine-Resistant Mutational Patterns with the Antiviral Effect of Adefovir in Patients with Chronic Hepatitis B
… B virus polymerase mutations 8 D. Effect of lamivudine-resistant mutational pattern on the virologic and biochemical response to adefovir 12 IV. DISCUSSION 15 V. CONCLUSION 18 REFERENCES 19 국문요약 24 "
-
Association of HBV DNA and ALT Level with YMDD motif Mutation Type in Lamivudine Resistance for Chronic Hepatitis B
BACKGROUND: The emergence of lamivudine resistant hepatitis B virus(HBV), with point mutation in the YMDD motif of DNA polymerase gene, has been reported in chronic hepatitis B patients with lamivudine treatment. The aim of this study was to investigate the distribution patterns and clinical …
-
Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine resistant chronic hepatitis B patients
… effectively inhibits both wild-type and lamivudine-resistant hepatitis B virus replication. The development of adefovir resistance is delayed and infrequent compared with lamivudine resistance. The aim of this study was to characterize the serologic, biochemical and virologic response to …
-
HBV genotypes at the Groote Schuur Hospital Liver Clinic, Cape Town : genotype and subgenotype prevalence and the influence of ethnicity on treatment outcomes during long term clinical follow-up of patience with chronic HBV infection.
… work investigating the possible presence of lamivudine resistant strains in lamivudine na'ive patients are reported. This is important as the increase in incidence of lamivudine use in HBV-HIV co-infected patients may have potential implications in lamivudine treatment management programmes. …
-
Cost effectiveness analysis of abacavirlamivudine versus tenofoviremtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients
… transcriptase inhibitors, namely abacavir/lamivudine or tenofovir/emtricitabine. This study is to compare the cost-effectiveness of these two alternatives in the treatment of HIV treatment-naive patients. Methods: A review of the literature was performed to identify relevant randomized …
-
Supramolecular modification of selected antiretroviral drugs
… complexation with nevirapine, efavirenz, lamivudine and zidovudine, with a view to identifying and isolating new solid forms of these drugs. Any new forms were to be characterised by a variety of analytical techniques, including thermal, spectroscopic and X-ray analysis and, where …
-
Desenvolvimento de método indicativo de estabilidade para detecção de produtos de degradação da associação de zidovudina e lamivudina (300 + 150 mg) em matéria-prima e comprimidos.
… 36) for related substances tablet zidovudine and lamivudine associated through stress tests in alkaline, acidic, neutral and oxidative. The results were analyzed based on the interpretation of the chromatograms generated by High Efficiency Liquid Chr omatography (HPLC) with diode array detector …
-
Prevalence of Hepatitis B in HIV infected persons: choice of antiretroviral therapy regimen and implications for screening
… antiviral treatment, namely tenofovir and/or lamivudine. The relationship between Hepatitis B carriage and liver function was also determined in co-infected persons as measured by liver function tests. A cross sectional study was conducted from 30th August 2011 to 24th April 2013 to determine …
-
Stereoselective and Economical Methods for Chemical Synthesis of Essential Medicines
… synthesis of small molecule drugs emtricitabine, lamivudine, bedaquiline, and diazepam was investigated. Stereoselective strategies and cost-of-goods reduction more broadly are described. Lastly, a perspective on reproductive health safety in the chemical laboratory is presented. Chapter 1: …
-
Retention in care among HIV-infected women initiating ART during pregnancy: a cohort study
… and women initiated a regimen of tenofovir, lamivudine and efavirenz. Women eligible for ART were either referred to general adult ART services nearby (January-December 2011) or received ART integrated into ANC services (January-September 2012). Outcomes were measured up to six months …
-
Development and characterization of an in vitro culture system as a physiological model for chronic Hepatitis B infection
… currently available therapeutics (e.g. IFNca, lamivudine, adefovir, etc.) that include limited efficacy and the promotion of drug-resistant viral strains. These therapeutics are the research products of the HBV molecular biology that can be manipulated in the laboratory setting. Future …
-
Clinical Course of Partial Virological Responders
… nucleot(s)ide analogue (NUC)-naïve and 28 were lamivudine (LAM)-experienced. The cumulative rates of VR were 54.1%, 70.8%, and 83.7% for the NUC-naïve group and 37.0%, 42.8%, and 42.8% for the LAM-experienced group after 24, 36, and 48 months of ETV therapy, respectively (P=0.008). Low HBV DNA …
-
Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
… in 45 patients. (25 with entecavir, 14 with lamivudine, 6 with adefovir.) All patients had followed up at least 1 year after stopping NUC therapy. Serum ALT, AST and HBV DNA levels were measured every 3 months. Clinical relapse was defined as HBV DNA>2,000 IU and ALT or AST > 2 times of upper …
-
Impact of DTG Use During Pregnancy on Birth Outcomes of HIV-Infected Women in the Western Cape, South Africa
Background: The global shift to tenofovir+lamivudine+dolutegravir (TLD) has improved viral suppression in pregnant women living with HIV (WLH) but there are limited data on the combined impact of HIV and maternal body composition on birth outcomes. Methods: We enrolled WLH on TLD and a comparison …
Page 1 of 2